◼ Archived
Business
Cellectis will shed 70% of workforce as part of in vivo pivot
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.
1 trends tracked about this subject — the full history, oldest to newest below.
Cellectis announces 70% workforce reduction and strategic pivot to in vivo gene editing as Q3 revenue drops to $14.8M.